
Please try another search
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Sanjay S. Shukla | 52 | 2016 | President, CEO & Director |
Timothy P. Coughlin | 57 | 2017 | Independent Chairman of the Board |
Paul R. Schimmel | 84 | 2005 | Independent Director |
Susan L. Ackerman | - | - | Member of Scientific Advisory Board |
Svetlana Lucas | 53 | 2019 | Independent Director |
Jane A. Gross | 68 | 2019 | Independent Director |
Sara L. Zaknoen | 66 | 2021 | Independent Director |
Eric S. Benevich | 60 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review